The diagnostics landscape for sexually transmitted infections

Overview

This
document highlights the diagnostics available now to support scale-up
and expanded access to screening to meet the growing testing demands in low- and middle-income countries (LMICs).

The focus of this landscape is
on the technologies (tests, platforms and systems for use in
resource-limited settings) commercially available at the time of
publication for syphilis, chlamydia, gonorrhoea, trichomoniasis,
mycoplasma, herpes, and human papillomavirus.

This document does not provide
market assessments or pipelines for new technologies but recognizes the
need for additional complimentary documents to support decision makers
in prioritizing STI testing in LMICs. The target audience for this
document is broad but includes mainly national program managers.